Ophirex
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5643 Paradise Dr Ste 2, Corte Madera, Ca...Phone Number
(415) 891-8682Website
www.ophirex.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Ophirex
Ophirex, a public benefit corporation focused on global health, is committed to addressing the medical needs associated with snakebite and other life-threatening bites and stings, as well as diseases and conditions with related mechanisms of illness and injury. The company is focused on developing an affordable, accessible, oral treatment for snakebite envenoming.Explore more
Ophirex Org Chart
Get the full picture
Sign in to uncover key details.
SO
Director, Clinical Research
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ophirex your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Ophirex has new funding data
Ophirex, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Ophirex is spiking on competitors!
Check if Ophirex has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Ophirex recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Ophirex
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Ophirex launches new products
Click to see if Ophirex had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Ophirex as Masked Content
Find more new buyers
Compare Similar Companies to Ophirex
Compare insights from companies similar to Ophirex, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ophirex is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ophirex is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ophirex.
Ophirex financials insights
Gather financial insights about Ophirex, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series B
$37M
Ophirex Tech Stack
A closer look at the technologies used by Ophirex
Most Recent Scoops
Person-Based
Funding
Project
Spending/Investment, Clinical Operations, Operations
Funding
Funding
Ophirex News & Media
Ophirex Announces Business Update: Advances Toward Food and Drug Administration (FDA) Approval for Varespladib as Novel Oral Snakebite Treatment
Ophirex announces regulatory and business developments as it continues to advance varespladib as the first oral rescue treatment for snakebite.Ophirex Publishes Phase 2 Data in BMJ Global Health from the First Use of Varespladib to Treat Venomous Snakebite Victims
CORTE MADERA, Calif.--(BUSINESS WIRE)--Ophirex, Inc., a Public Benefit Corporation developing an oral treatment to address the unmet medical needs of snakebite victims globally, today announced that BMJ Global Health has published data from the company’s BRAVO trial evaluating oral varespladib. Varespladib is a small synthetic molecule that directly inhibits secretory phospholipase A2 (sPLA2), an enzyme that is present in more than 95% of all snake venoms. The oral form is being developed as anOphirex Appoints Jeremy Gowler as Chief Executive Officer
CORTE MADERA, Calif.--(BUSINESS WIRE)--Ophirex, Inc. appoints Jeremy Gowler as chief executive officerOphirex Completes $37 Million Series B Financing to Advance Development of Broad-Spectrum Snakebite Treatment
CORTE MADERA, Calif.--(BUSINESS WIRE)--Ophirex, Inc., a public benefit biotechnology company, today announced the successful completion of a $37 million Series B financing, led by AXA IM Prime Impact Master Fund I SCA SICAV-RAIF. The proceeds are expected to fund continued clinical development, regulatory submission, and anticipated launch of Ophirex’s lead drug candidate, varespladib, as an oral, broad-spectrum treatment for snakebite envenoming. Ophirex recently reached full enrollment of its
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ophirex
Sign Up For FreeTo access detailed company insights
Ophirex, a public benefit corporation focused on global health, is committed to addressing the medical needs associated with snakebite and other life-threatening bites and stings, as well as diseases and conditions with related mechanisms of illness and injury. The company is focused on developing an affordable, accessible, oral treatment for snake... Read More
